All In Biotech

Drug Trial Radar · NCT05374512

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 644 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

644

Actual

Start

May 16, 2022

Primary completion

Aug 25, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
May 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Conditions

  • Breast Cancer

Interventions

  • Dato-DXdDrug

    Experimental drug. Provided in 100mg vials. IV infusion.

  • PaclitaxelDrug

    IV Infusion. Active comparator

  • Nab-paclitaxelDrug

    IV infusion. Active comparator

  • CarboplatinDrug

    IV infusion. Active comparator

  • CapecitabineDrug

    Tablet. Oral route of administration. Active comparator

  • Eribulin mesylateDrug

    IV infusion. Active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)
  2. Overall Survival (OS)Time frame: From randomisation until the date of death due to any cause (approximately 42 months)

Locations

228 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Francisco, California

  • Research Site

    Grand Junction, Colorado

  • Research Site

    Longmont, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Louisville, Kentucky

  • Research Site

    Detroit, Michigan

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Providence, Rhode Island

  • Research Site

    Sioux Falls, South Dakota

  • Research Site

    Memphis, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Kingwood, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Spokane Valley, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad Autónoma Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Sint-Niklaas, Belgium

  • Research Site

    Wilrijk, Belgium

Showing 40 of 228 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.